Robyn Karnauskas

Amgen Wins Big With FDA, Analyst Sees Soaring Potential

Analysts Focus On Gilead's Late-Stage Data Readouts Following Mixed Q4

Gilead Sciences Outlook Brightens; Citi Upgrades

Analysts Focus On Gilead's Late-Stage Data Readouts Following Mixed Q4

Gilead Sciences Outlook Brightens; Citi Upgrades

Wall Street Reacts To Celgene's Reported Interest In Juno

Citi Downgrades Regeneron, Citing 'Underappreciated' Risk

Wall Street Reacts To Celgene's Reported Interest In Juno

Citi Downgrades Regeneron, Citing 'Underappreciated' Risk

Biogen Bull Thesis Baked In, No Longer A Buy At Citi

What To Do With Celgene Now With Major Catalysts Gone

Robyn Karnauskas Recent News

A Decade Of Sales Growth Lies Ahead For Vertex Pharmaceuticals

Bluebird News A Positive For Juno, Kite Pharma

Citi Starts Calithera Biosciences At Sell On Cash Burn And Lack Of Near-Term Catalysts

Citi Launches Positive Coverage On Five Prime Therapeutics

Citi Sees 26% Upside In TESARO On The Strength Of Trial Data

Citi Sees Kadmon's Trials As 'Risky,' Initiates With Neutral Rating

Citigroup Upgrades Bellicum Pharma, Sees Clearer Pathway For BPX-501 Approval

Citi Raises TESARO Price Target 38%, Sees 16.3% Upside

Alexion Pharma Brexit Selloff Creates An Entry Point: Trading At 'Dark-Sky' Valuation

Regeneron CEO And CFO Met With Citi: Here Are The Takeaways

Lingo Failure Leads Citi To Downgrade Biogen

Solid Potential For Gilead To Beat Estimates And Raise Guidance: Here's How

Has A Biotech Recovery Started Yet?

Citi Surprised, Confused Amid Report Biogen May Divest Hemophilia Unit

Citi: Buy Celgene, Gilead, Biogen And Regeneron As Biotechs Recover

Wall Street's Best Think Gilead Will Continue To Outperform The Market

Wall Street Mixed On Biogen Before Earnings

Deutsche Bank Bullish On Biogen: New Data Doesn't Change Probability Of Success For Alzheimer's

BioMarin's Results Are In: What Do They Mean?

Deutsche Sees Cancer Treatment Home Run At Infinity Pharmaceuticals

This Data Offers Insight Into Gilead Sales

Gilead Alert: What Deutsche Bank Is Saying

Why BioMarin Pharmaceutical Is Surging